Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies


The engine driving most small molecule discovery programs is the biological chemistry and drug discovery team.

Sygnature’s chemistry department is one of the largest and most experienced medicinal chemistry groups in the UK with over 85% of chemists possessing a PhD. It has provided expert synthetic, analytical and medicinal chemistry resource to multiple successful client programs.

Biological Chemistry and Drug Discovery

Our medicinal chemists work closely with computational chemistry, bioscience and DMPK teams to assemble a project-specific screening cascade that addresses the key challenges at each stage of the project. Our close proximity and state of the art informatics system allows a very rapid design-make-test-analyse cycle to efficiently inform decision making.

Sygnature’s team has frequently been finalists in the UK retro-synthesis competition and this high level of innovative chemistry allows us to tackle even the most challenging medicinal programs. Our investment in modern analytical instrumentation provides our chemists with the tools needed to isolate and fully characterise the molecules we make.

Chemistry Services

Medicinal Chemistry

Recognising the best path to an optimal drug profile requires experience and understanding. With Sygnature’s team your drug discovery program is in safe hands.


Synthetic Chemistry

Innovative synthetic chemistry makes a huge difference when seeking to generate novel patentable molecules with optimised properties.


Analytical Chemistry

Providing full confidence in the structure and purity of our molecules.


High Throughput Chemistry

Sygnature has a well-established HTC lab which has been efficiently producing small, diverse libraries for the European Lead Factory for the past 5 years.


Latest News

View All

Sygnature Discovery and Daewoong Pharma announce research…

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…